FDA orders a partial hold on Epizyme’s lead cancer drug tazemetostat following T-cell lymphoma case
Epizyme $EPZM is in some hot water this evening after the biotech revealed a partial clinical hold on its crucial program for tazemetostat.
The Cambridge, MA-based biotech was forced to slam the brakes on any enrollment for its clinical trials of the drug for now as investigators sort out a pediatric case of secondary T-cell lymphoma.
Investors didn’t like it. The biotech’s shares tanked 18% in after-market trading.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.